Microstructured Reactors for Rapid Process Development and Scale-Up - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Microstructured Reactors for Rapid Process Development and Scale-Up
The authors discuss a continuous-flow reactor that avoids parallel channels and enables economic plant setup. This article is part of a special issue on API Development, Formulation, Synthesis and Manufacturing.


Pharmaceutical Technology
pp. s32-s36

Conclusion

After more than a decade of microstructured devices in chemical production, the implementation of microreactors is essentially understood. The interaction of chemistry, reaction kinetics, involved phases, and transport phenomena plays the crucial role in appropriate reactor and plant design. It is important to determine the limiting steps in time scales and heat management. It is possible to run continuous processes in microstructured devices at the laboratory scale, and these processes can be scaled up to pilot and production scale with low risk. This multiscale production potential from grams to tons allows a high flexibility and offers short time-to-decision in a project.

The Lonza MicroReactor technology represents a consistent and comprehensive scale-up approach and has benefits for the process research and development and manufacturing departments of fine-chemical and pharmaceutical companies. The technology illuminates a clear path from laboratory chemistries to large-scale manufacturing processes, and it completely avoids the parallelization strategies that may result in technical problems. This reactor platform supports rapid process development and production under continuous-flow conditions using microstructured elements. The developed reactor technology is modular, robust, multipurpose, and scalable and has already been tested for several products and processed tons of material during a campaign of a few weeks.

Norbert Kockmann is a senior scientist, Michael Gottsponer is a laboratory chemist, Markus Eyholzer is a laboratory technician, and Dominique M. Roberge* is responsible for business development, all at Lonza, CH-3930 Visp, Switzerland, tel. +41 0 27 948 50 27, fax +41 0 27 947 50 27,
.

*To whom all correspondence should be addressed.

References

1. K. Geyer, J.D.C. Codée, and P. Seeberger, Chemistry 12 (33), 8434–8442 (2006).

2. T.Y. Zhang, Chem. Rev. 106 (7), 2583–2595 (2006).

3. N. Kockmann, Transport Phenomena in Micro Process Engineering, (Springer, Berlin, 1st ed., 2008).

4. J.I. Yoshida, Flash Chemistry, (Wiley-VCH, Weinheim, Germany, 1st ed., 2008).

5. L. Ducry and D.M. Roberge, Angew. Chem. Int. Ed. Engl. 44 (48), 7972–7975 (2005).

6. H. Pennemann, V. Hessel, and H. Löwe, Chem. Eng. Sci. 59 (22–23), 4789–4794 (2004).

7. Ehrfeld Mikrotechnik BTS, http://www.ehrfeld.com/, accessed July 30, 2010.

8. N. Kockmann et al., Chemistry 14 (25), 7470–7477 (2008).

9. D.M. Roberge et al., Chem. Eng. Technol. 28 (3), 318–323 (2005)

10. N. Kockmann and D.M. Roberge, Chem. Eng. Technol. 32 (11), 1682–1694 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here